StockData
Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) stock

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.90−0.03 (-1.55%)

Close on Nov 17, 2026Market cap $18.96MP/E –Yield –

Atossa Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Atossa Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.20M, up 28.7% year over year. For fiscal 2025 it was $21.19M, up 50.1% from the year before. Over ten years it grew 24.5% a year on average. The highest annual figure on record is $21.19M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$21.19M+50.1%
FY2024Dec 31, 2024$14.12M-18.6%
FY2023Dec 31, 2023$17.33M+14.9%
FY2022Dec 31, 2022$15.08M+63.8%
FY2021Dec 31, 2021$9.21M+39.4%
FY2020Dec 31, 2020$6.61M-0.6%
FY2019Dec 31, 2019$6.65M+57.8%
FY2018Dec 31, 2018$4.21M+80.8%
FY2017Dec 31, 2017$2.33M+202.2%
FY2016Dec 31, 2016$770.43K-67.3%
FY2015Dec 31, 2015$2.36M+112.5%
FY2014Dec 31, 2014$1.11M+0.5%
FY2013Dec 31, 2013$1.11M-44.0%
FY2012Dec 31, 2012$1.97M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.90M-11.0%
Q1 FY2026Mar 31, 2026$4.78M+15.0%
Q4 FY2025Dec 31, 2025$6.16M+80.9%
Q3 FY2025Sep 30, 2025$5.37M+57.4%
Q2 FY2025Jun 30, 2025$5.50M+54.9%
Q1 FY2025Mar 31, 2025$4.16M+10.9%
Q4 FY2024Dec 31, 2024$3.40M-39.8%
Q3 FY2024Sep 30, 2024$3.41M-23.6%
Q2 FY2024Jun 30, 2024$3.55M-4.1%
Q1 FY2024Mar 31, 2024$3.75M+6.8%
Q4 FY2023Dec 31, 2023$5.65M+13.4%
Q3 FY2023Sep 30, 2023$4.47M-13.4%
Q2 FY2023Jun 30, 2023$3.71M+7.9%
Q1 FY2023Mar 31, 2023$3.51M+134.0%
Q4 FY2022Dec 31, 2022$4.99M+172.9%
Q3 FY2022Sep 30, 2022$5.16M+133.9%
Q2 FY2022Jun 30, 2022$3.43M-9.6%
Q1 FY2022Mar 31, 2022$1.50M+8.7%
Q4 FY2021Dec 31, 2021$1.83M-22.5%
Q3 FY2021Sep 30, 2021$2.21M+33.0%
Q2 FY2021Jun 30, 2021$3.80M+129.8%
Q1 FY2021Mar 31, 2021$1.38M+46.9%
Q4 FY2020Dec 31, 2020$2.36M+162.5%
Q3 FY2020Sep 30, 2020$1.66M-1.5%
Q2 FY2020Jun 30, 2020$1.65M-36.7%
Q1 FY2020Mar 31, 2020$938.62K-35.3%
Q4 FY2019Dec 31, 2019$898.02K+5.7%
Q3 FY2019Sep 30, 2019$1.68M+18.5%
Q2 FY2019Jun 30, 2019$2.61M+78.0%
Q1 FY2019Mar 31, 2019$1.45M+208.1%
Q4 FY2018Dec 31, 2018$849.42K+291.0%
Q3 FY2018Sep 30, 2018$1.42M+91.5%
Q2 FY2018Jun 30, 2018$1.47M+78.1%
Q1 FY2018Mar 31, 2018$470.98K-13.5%
Q4 FY2017Dec 31, 2017$217.24K-40.7%
Q3 FY2017Sep 30, 2017$742.45K+773.5%
Q2 FY2017Jun 30, 2017$824.09K–
Q1 FY2017Mar 31, 2017$544.30K–
Q4 FY2016Dec 31, 2016$366.46K–
Q3 FY2016Sep 30, 2016$85.00K–

More Atossa Therapeutics figures

See a number that looks wrong?